Germany Germany is the default first-choice European market for launching new, innovative medicines. But with the country’s pricing system under growing strain from both national and international pressures, some in the industry are asking how long that status can hold.   Germany is, by far, Europe’s leading country for fast and…

Global The global contract manufacturing market is booming, but fragmented. The well-established names of the CDMO space – Lonza, Thermo Fisher, WuXi AppTec, WuXi Biologics, and Samsung Biologics – account for just 15 percent of total revenues.   Beyond these giants, a huge network of smaller, more specialised CDMOs are, in…

China Chinese biotechs are now outpacing multinationals at getting drugs into pivotal trials — but MNCs still win the race to final approval. In this piece from the September 2026 edition of DIA Global Forum, Li Wang of Lilly’s China Drug Development & Medical Affairs Center digs into fresh 2023–2025 timeline…

Singapore Singapore’s Health Sciences Authority has become one of the world’s most respected drug regulators, earning WHO maturity level 4 status and a seat at tables like the Access Consortium and Project Orbis. Writing in the September 2026 edition of DIA Global Forum, Sandy Chan, Sok Bee Lim, Shirley Yong, and…

Global Biosimilars have already saved health systems billions of dollars, yet adoption still varies wildly by geography. With a wave of major biologics losing patent protection this decade, the market opportunity is enormous, as is the potential impact for government coffers and patients. Can Europe maintain its position as the industry’s…

France Sanofi’s new CEO Belén Garijo has taken the reins of a company with healthy growth, but three recent late-stage clinical trial failures and a looming patent cliff for its biggest product. She arrives with a reputation as one of European pharma’s most decisive leaders – but a patchy record on…

Korea Multi-million dollar deals, world-first approvals, and a new willingness to be patient are transforming how Korea’s biotech sector does business. Korean biotech companies want to hold onto their molecules for longer. That was the message from nearly every biotech executive PharmaBoardroom spoke with in a series of recent interviews in…

Europe Rock-bottom prices, regulatory red tape, and intense competition from Asia have made life difficult for Europe’s generics and biosimilar producers. Yet a handful of companies are not just surviving this squeeze but thriving in it – through diversification, geographic focus, R&D intensity, or sheer scientific specialisation. Here’s how four of…

China Chinese pharmaceutical companies are increasingly seeking drug approval in the EU, US, and Australia, beyond the NMPA. Daphne Smyth of Veristat has witnessed this shift firsthand, advising sponsors on data gaps, supplementary studies, and the regulatory quirks that stand in the way of a drug developed in China gaining marketing…

USA Neuroscience is back. After a litany of divestments and scale backs in the 2010s, diseases of the brain are now the second-most-funded area in biotech, behind only cancer. However, this remains a complex and challenging field, leading neuroscience biotechs – three of which are profiled below – to develop very…

Europe The European Commission has set itself an ambitious target: making Europe the world’s most attractive destination for life sciences by 2030. In recent conversations with PharmaBoardroom, executives leading Europe for AbbVie, BeOne Medicines, CSL, Merz Therapeutics, and Novartis would love to see this realised and agree that Europe’s scientific fundamentals…

Global Five conferences, anxiety spreading across five continents, one unmistakable pattern: the global pharmaceutical industry is transforming at a dizzying pace. From Philadelphia to Geneva, from Istanbul to Chicago and London, the Shawview Consulting team picked up the same recurring threads in every panel and hallway conversation: AI and real-world data…